Onesource Specialty Pharma Ltd — Q4 FY26 earnings call
Summary generated by AI from the official transcript Onesource Specialty Pharma Ltd filed with BSE on 19 May 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
OneSource reported a sequential recovery in Q4 FY26 with revenue of INR4,282 million, up 47% quarter-over-quarter, driven by the India Semaglutide launch and broad-based improvement across service lines. EBITDA rose more than 5x sequentially to INR919 million, while full-year revenue declined 2% and EBITDA declined about 35% year-on-year due to delayed Semaglutide approvals in Canada earlier in the year. Management reiterated its FY28 guidance of US$400 million organic revenue with around 40% EBITDA margin and confirmed the Steriscience/Brooks scheme has been deferred following shareholder concerns on valuation.
Numbers mentioned
Revenue: INR4,282 million (Q4 FY26)
p. 6
“in the fourth quarter, our revenues stood at INR4,282 million.”
Anurag Bhagania, page 6 of the filed PDF · View the filing
Revenue: INR14,216 million (FY26)
p. 6
“On a full year basis, we reported INR14,216 million, which is a 2% decline year-on-year.”
Anurag Bhagania, page 6 of the filed PDF · View the filing
EBITDA: INR919 million (Q4 FY26)
p. 7
“On the profitability side, the Q4 EBITDA reported was INR919 million, which is more than 5x sequentially and the margin expanding by 1,550 basis points quarter-over-quarter, reflecting a strong operating leverage on our higher CSA revenues.”
Anurag Bhagania, page 7 of the filed PDF · View the filing
Adjusted PAT: INR390 million (Q4 FY26)
p. 7
“adjusted PAT for the quarter is about INR390 million compared to a loss in the previous quarter.”
Anurag Bhagania, page 7 of the filed PDF · View the filing
Adjusted PAT: INR739 million (FY26)
p. 7
“For the full year FY '26, adjusted PAT stood at INR739 million.”
Anurag Bhagania, page 7 of the filed PDF · View the filing
EPS: INR3.4 (Q4 FY26)
p. 7
“our EPS for the quarter is INR3.4 on a fully diluted basis and INR6.5 for the full year.”
Anurag Bhagania, page 7 of the filed PDF · View the filing
Cost of borrowing: below 9%
p. 7
“We are trending below 9% today, which is 210 bps lower than what it was in the prior year.”
Anurag Bhagania, page 7 of the filed PDF · View the filing
Revenue growth: 47% (Q4 FY26 vs Q3 FY26)
p. 5
“the revenues at almost US$48 million, up almost 47% from the previous quarter.”
Neeraj Sharma, page 5 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Revenue — US$400 million · FY28
stated firmly by Arun Kumar
p. 3
“we're also using the opportunity today to reaffirm our long-term guidance of FY '28, which is a US$400 million of organic revenue with around 40% of EBITDA margins.”
Arun Kumar, page 3 of the filed PDF · View the filing
EBITDA margin — around 40% · FY28
stated firmly by Arun Kumar
p. 3
“we're also using the opportunity today to reaffirm our long-term guidance of FY '28, which is a US$400 million of organic revenue with around 40% of EBITDA margins.”
Arun Kumar, page 3 of the filed PDF · View the filing
Second manufacturing line availability — Q2
stated firmly by Arun Kumar
p. 3
“Our second line is now at site and is going engineering and qualification trials, and we expect that capacity to be available to us in Q2, in time with increasing demands for the product from emerging markets.”
Arun Kumar, page 3 of the filed PDF · View the filing
ROCE — 50% plus · medium term
stated as an aspiration by Anurag Bhagania
p. 7
“We expect to scale meaningfully, building towards the 50% plus ROCE expectation that we have for ourselves during the medium term.”
Anurag Bhagania, page 7 of the filed PDF · View the filing
Working capital — FY27
stated conditionally by Anurag Bhagania
p. 7
“we expect this to normalize during the course of the year in FY '27.”
Anurag Bhagania, page 7 of the filed PDF · View the filing
Number of manufacturing lines installed — three lines · end of FY27
stated firmly by Neeraj Sharma
p. 10
“I'm just staying put with three lines which will be ready and which will be visible by end of FY27.”
Neeraj Sharma, page 10 of the filed PDF · View the filing
Steriscience/Brooks scheme — about two years
stated conditionally by Arun Kumar
p. 4
“we will re-look at these opportunities probably in about two years from now, if at all there is a need and the strategic intent is still valid at that time.”
Arun Kumar, page 4 of the filed PDF · View the filing
Soft gelatine capacity utilization — fully utilized · within current period
stated firmly by Neeraj Sharma
p. 15
“by within the current period, we look at this capacity to be fully utilized.”
Neeraj Sharma, page 15 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said the duty only applies when local manufacturing exists, which it currently doesn't in Brazil, and terms with customers are ex-works so tariff impact falls on customers; they declined to comment on profit-sharing terms with other customers, citing confidentiality.
Answered by Neeraj Sharma
Asked by Rupesh Tatiya: How will Brazil's local manufacturing duty of 28% affect growth, and are profit-sharing arrangements similar with other customers in regulated markets?
p. 8
“as a CDMO, all our terms with our customers are ex-works.”
Neeraj Sharma, page 8 of the filed PDF · View the filing
Management clarified that inventories are fully funded by customers and fungible across them, carrying no risk to the company.
Answered by Anurag Bhagania
Asked by Rupesh Tatiya: Why have inventories risen sharply from INR158 crores to INR440 crores for the drug device combination business?
p. 8
“these purchases are fully funded by our customers and fungible.”
Anurag Bhagania, page 8 of the filed PDF · View the filing
Management said the opex investment supports the $400 million revenue guidance and capacity expansion, particularly the DDC business coming online with new lines.
Answered by Neeraj Sharma
Asked by Chirag Shah: What revenue scale will the increased staff cost and opex support, and what are non-CDMO business margins?
p. 9
“It is for supporting our guidance of $400 million revenue.”
Neeraj Sharma, page 9 of the filed PDF · View the filing
Management explained the new line undergoing qualification will be available next quarter, with a third line coming online later, giving three lines with roughly 675 sterile days of capacity by end of FY27.
Answered by Neeraj Sharma
Asked by Nitin Agarwal: What is the capacity expansion timeline for DDC and when will utilization ramp up?
p. 10
“That line will be available from next quarter onwards.”
Neeraj Sharma, page 10 of the filed PDF · View the filing
Management said biologics has a long gestation period for signing agreements, with meaningful contribution expected in FY27 and FY28, and commercial manufacturing beginning around FY29.
Answered by Neeraj Sharma
Asked by Nitin Agarwal: When will the biologics business contribute meaningfully to consolidated EBITDA?
p. 11
“We see the commercial manufacturing happening '29 onwards. However, the contribution from biologics will already be meaningful in FY28.”
Neeraj Sharma, page 11 of the filed PDF · View the filing
Management said customers have made capacity reservations including upfront fees and take-or-pay contracts to secure supply access.
Answered by Neeraj Sharma
Asked by Kunal Lakhan: Do customers have minimum volume commitments for Semaglutide regardless of their own sales?
p. 12
“customers have done capacity reservation with us. And that capacity reservation includes blocking capacity and submitting to pick up that capacity both by paying upfront fee as well as take-or-pay kind of contract.”
Neeraj Sharma, page 12 of the filed PDF · View the filing
Management said Brazil is the largest market outside North America for Semaglutide given its population size and focus on weight reduction, and other markets like Turkey and Saudi Arabia are also significant due to population, though supply has historically been constrained.
Answered by Neeraj Sharma
Asked by Aniket Singh: How large could the Brazil and other ROW Semaglutide markets be?
p. 13
“Brazil today, if you look at IQVIA, Brazil is the largest market outside of North America for Semaglutide, right?”
Neeraj Sharma, page 13 of the filed PDF · View the filing
Management clarified the delay was due to an India patent constraint rather than a Saudi patent issue, and the Saudi launch is now imminent.
Answered by Neeraj Sharma
Asked by Ritika: Why was there a delay in Saudi Arabia Semaglutide launch despite an earlier approval notification?
p. 14
“Now that all that is freedom to operate is there, so as we have said, Saudi launch is imminent.”
Neeraj Sharma, page 14 of the filed PDF · View the filing
Management declined to break down financials by business line citing customer confidentiality, but said the business would contribute meaningfully to FY28 numbers and beyond.
Answered by Neeraj Sharma
Asked by Aman Vij: What is the biologics business revenue/EBITDA loss for FY26 and when will it break even?
p. 15
“we don't really break down business-wise revenue or any other financial.”
Neeraj Sharma, page 15 of the filed PDF · View the filing
Management said orals may capture 25% to a third of the total market due to lower efficacy, high pill burden, and daily dosing side effects, with the market remaining overwhelmingly injectable.
Answered by Neeraj Sharma
Asked by Kartick Bane: What impact will oral Semaglutide have on the business?
p. 16
“we don’t expect the orals to be taking about anywhere between 25% to maybe a third of the total market.”
Neeraj Sharma, page 16 of the filed PDF · View the filing
Management confirmed Dr. Reddy's as one partner and Orbicular, which has a partner among the largest Canadian companies, as the other.
Answered by Neeraj Sharma
Asked by Kartick Bane: Is the Canadian partner an Indian or non-Indian company?
p. 16
“it’s one company is in public domain, which is Dr. Reddy's.”
Neeraj Sharma, page 16 of the filed PDF · View the filing
Risks flagged
Deferral of the Steriscience/Brooks scheme due to shareholder concerns over valuation after the listed company's share price dropped from the intended valuation.
p. 4
“the pricing of both -- I mean, the pricing of the listed company significantly dropped from the intended valuation price of approximately INR2,200 -- a share, we decided that it's best that we defer this transaction”
Arun Kumar, page 4 of the filed PDF · View the filing
Full-year EBITDA decline due to delayed Semaglutide approvals in Canada affecting the second half of results.
p. 7
“For the full year, the EBITDA declined about 35% due to delayed Semaglutide approvals which weighed in on our second half of the results.”
Anurag Bhagania, page 7 of the filed PDF · View the filing
Regulatory change on the new Labour Code requiring a provision as an exceptional item.
p. 7
“there is a significant regulatory change on the new Labour Code during this year. During the course of the year, we've already fully provided for this change as an exceptional item in our current year's financials.”
Anurag Bhagania, page 7 of the filed PDF · View the filing
Oral Semaglutide has lower efficacy, high pill burden and daily dosing side effect challenges compared to injectables.
p. 16
“orals have a challenge of [inaudible] they still don't match the efficacy of injectables. Orals also require a daily dosing, what we call a very high pill burden.”
Neeraj Sharma, page 16 of the filed PDF · View the filing
Difficulty forecasting timing of additional Semaglutide approvals for other clients in Canada since it is not directly involved in regulatory strategy.
p. 13
“that's a question which we are not directly involved in managing the regulatory strategy or discussing with the regulatory agencies.”
Neeraj Sharma, page 13 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.